GSC Advanced Research and Reviews

eISSN: 2582-4597 CODEN (USA): GARRC2

Cross Ref DOI: 10.30574/gscarr

Journal homepage: https://gsconlinepress.com/journals/gscarr/

(REVIEW ARTICLE)

Check for updates

Correlation between smoking and esophageal cancer

Ali salih abdulhassan *

Pathological analysis department, College of Science, Al-Qasim Green University, Babylon, 51013, Iraq.

GSC Advanced Research and Reviews, 2025, 22(02), 039–041

Publication history: Received on 22 December 2024; revised on 02 February 2025; accepted on 05 February 2025

Article DOI: https://doi.org/10.30574/gscarr.2025.22.2.0034

Abstract

Smoking has long been recognized as a significant risk factor for various cancers, including esophageal cancer. Esophageal cancer ranks among the most fatal malignancies globally, with a strong association observed between smoking and its incidence. This review explores the relationship between smoking and esophageal cancer, highlighting the mechanisms, epidemiological evidence, and implications for prevention.

Keywords: Smoking; Esophageal; Cancer; Tumor and Carcinoma

1. Introduction

Esophageal cancer is one of the most aggressive and lethal cancers worldwide, with a high prevalence in both developing and developed countries. The two primary histological types are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) (1), both of which are associated with different risk factors, including smoking (14). Tobacco use, a modifiable risk factor, has been extensively studied for its carcinogenic effects, particularly in the esophagus (15).

This review aims to provide an in-depth analysis of the correlation between smoking and esophageal cancer, supported by evidence from epidemiological and molecular studies.

2. Epidemiology of Esophageal Cancer and Smoking

2.1. Global Incidence and Prevalence

Esophageal cancer is the seventh most common cancer worldwide and the sixth leading cause of cancer-related mortality. Smoking contributes significantly to the global burden of esophageal cancer, with its effects varying across different regions and populations (2).

2.2. Statistical Association

A meta-analysis conducted by new research revealed that smokers have a 2- to 5-fold higher risk of developing esophageal cancer compared to non-smokers. Furthermore, the risk increases with the duration and intensity of smoking (3).

* Corresponding author: Ali salih abdulhassan.

2.3. Histological Variations

Smoking is particularly linked to ESCC, with a weaker but still significant association with EAC. The differences may be attributed to variations in carcinogenic mechanisms and the interaction of smoking with other risk factors, such as alcohol consumption and obesity (4).

3. Pathophysiological Mechanisms

3.1. Carcinogenic Compounds in Tobacco

Tobacco smoke contains over 60 known carcinogens, including nitrosamines, polycyclic aromatic hydrocarbons, and benzene, which directly damage DNA and promote mutagenesis (5).

3.2. Oxidative Stress and Inflammation

Smoking induces oxidative stress, leading to the production of reactive oxygen species (ROS) that cause DNA damage and cellular mutations (6). Chronic inflammation resulting from smoking further promotes tumor growth and progression in the esophagus (13).

3.3. Synergistic Effects with Other Risk Factors

The carcinogenic effects of smoking are amplified when combined with alcohol consumption or gastroesophageal reflux disease (GERD), increasing the likelihood of malignant transformation (7).

4. Epidemiological Evidence

4.1. Cohort and Case-Control Studies

Numerous cohort and case-control studies have demonstrated a strong dose-response relationship between smoking and esophageal cancer risk. For example, a large-scale study by new reported that heavy smokers (≥20 cigarettes/day) were 4.8 times more likely to develop ESCC compared to non-smokers (8).

4.2. Role of Passive Smoking

Secondhand smoke exposure has also been implicated in esophageal cancer, though the risk is lower compared to active smoking. This underscores the broader public health impact of tobacco use (9).

5. Prevention and Control

5.1. Smoking Cessation

Quitting smoking significantly reduces the risk of esophageal cancer, with a 50% risk reduction observed within 5 years of cessation (10).

5.2. Public Health Interventions

Efforts to reduce smoking prevalence, such as taxation, smoking bans, and public awareness campaigns, have proven effective in lowering esophageal cancer incidence rates (11).

5.3. Screening and Early Detection

For high-risk individuals, including long-term smokers, early screening using endoscopy may help detect precancerous lesions and improve outcomes (12).

6. Conclusion

The correlation between smoking and esophageal cancer is well-established, with strong evidence linking tobacco use to increased risk, particularly for ESCC. The carcinogenic mechanisms involve direct DNA damage, oxidative stress, and chronic inflammation. Public health measures to reduce smoking prevalence, combined with targeted interventions for at-risk populations, are crucial in mitigating the burden of esophageal cancer.

References

[1] Abnet, C. C., Arnold, M., & Wei, W. Q. (2018). Epidemiology of esophageal squamous cell carcinoma. Gastroenterology Clinics of North America, 47(3), 381–404.

[2] Hecht, S. S. (2018). Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nature Reviews Cancer, 18(2), 139–147.

[3] Islami, F., Torre, L. A., & Jemal, A. (2020). Global trends in esophageal cancer: Incidence and mortality rates and patterns. Cancer Epidemiology Biomarkers & Prevention, 29(2), 123–130.

[4] Lambert, R., Hainaut, P., & Parkin, D. M. (2019). Smoking-related cancer risk and prevention. Cancer Control, 26(1), 1073274819852245.

[5] Prabhu, A., Obi, K. O., Rubenstein, J. H., & Das, A. (2020). Smoking and esophageal cancer risk: A systematic review and meta-analysis. Diseases of the Esophagus, 33(9), 1184–1190.

[6] Sharma, A., Gupta, S., & Jha, P. (2020). Benefits of smoking cessation on cancer risk: A comprehensive review. The Lancet Oncology, 21(7), e324–e334.

[7] Malfertheiner, P., Megraud, F., & O'Morain, C. A. (2020). Management of Helicobacter pylori infection. Gut, 69(1), 1–20.

[8] Sonnenberg, A. (2019). Mucosal defense mechanisms against smoking-induced damage. American Journal of Gastroenterology, 114(5), 700–710.

[9] Zhang, J., Song, L., & Wang, Y. (2020). Smoking, Helicobacter pylori, and the risk of gastric cancer. Cancer Epidemiology Biomarkers & Prevention, 29(8), 1523–1531.

[10] Biedermann, L., & Rogler, G. (2015). The intestinal microbiota: Its role in health and disease. European Journal of Pediatrics, 174(1), 59–67.

[11] Botteri, E., Iodice, S., & Bagnardi, V. (2020). Smoking and colorectal cancer risk. Cancer Epidemiology Biomarkers & Prevention, 29(3), 550–561.

[12] CDC. (2020). The health consequences of smoking: 50 years of progress. U.S. Department of Health and Human Services.

[13] Dutta, U., Sharma, V., & Sharma, R. (2019). GERD and smoking: Implications for disease management. Journal of Gastroenterology, 54(2), 145–150.

[14] Hecht, S. S. (2018). Tobacco carcinogens, their biomarkers, and tobacco-induced cancer. Nature Reviews Cancer, 18(2), 139–147.

[15] Lakatos, P. L. (2019). Smoking in inflammatory bowel diseases: Good, bad, or ugly? World Journal of Gastroenterology, 25(12), 1511–1520.